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Abstract
CYP3A4 present in small bowel enterocytes can catalyze substantial metabolism of some orally administered drugs and,
thus, exerts a first-pass effect. Recent data indicate that the P-glycoprotein (the MDR 1 gene product) in the enterocyte brush
border also limits the bioavailability of many of the same drugs that interact with CYP3A. It has been proposed that
P-glycoprotein and CYP3A4 may be functionally linked because (a) the two proteins are co-localized within the digestive
tract and within enterocytes, (b) they share many of the same substrates and (c) they are co-inducible in response to at least
some xenobiotics. There are several potential mechanisms whereby the functions of P-glycoprotein and CYP3A4 could be
complimentary. First, Pgp may limit absorption in the proximal small bowel, shifting it to more distal, less catalytically
efficient segments that contain lower amounts of CYP3A4. Second, Pgp may function to prolong the duration of absorption.
This might increase the duration of exposure of drug to and, hence, the extent of metabolism by enterocyte CYP3A4. Finally,
Pgp may preferentially remove from the enterocyte primary drug metabolites that are themselves substrates for CYP3A4.
This would limit product inhibition and facilitate primary metabolism catalyzed by CYP3A4. Characterization of the roles of
CYP3A4 and Pgp in limiting oral drug availability may be aided by recent success in the development of human intestinal
cell lines that stably express both CYP3A4 and Pgp.  1997 Elsevier Science B.V.
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1. Introduction kinetic properties of the reactions, appear to be
essentially identical in human small bowel and liver
1.1. Intestinal cytochrome P450 3A4 [3–6]. It therefore appears that catalytic properties of
CYP3A4 determined in human liver microsomes, or
There is now overwhelming evidence that some in recombinant systems, can generally be extrapo-
orally administered drugs that are substrates for lated to the small bowel.
cytochrome P450 3A4 (CYP3A4) can undergo sig- The related enzyme, CYP3A5, is also detectable in
nificant first-pass metabolism within small intestinal enterocytes in about 70% of adults, and is not co-
epithelial cells (enterocytes). These data are reviewed regulated with CYP3A4 [7–10]. Its structure, func-
elsewhere in this volume and will not be discussed tion and contribution to first-pass metabolism has not
extensively here. CYP3A4 appears to be the most been established. However, CYP3A5 appears to be a
abundant cytochrome P450 present in human small minor enterocyte enzyme in most individuals [7].
bowel [1,2]; it is found only in the mature en-
terocytes lining the villus and is not present in crypt 1.2. Intestinal P-glycoprotein
cells (Fig. 1). CYP3A4 present in human enterocytes
appears to be functionally and structurally identical The potential role of P-glycoprotein (Pgp, the
to CYP3A4 present in human liver. The complete MDR-1 gene product) in determining oral availabili-
coding region of intestinal CYP3A4 cDNA has been ty of some drugs has only recently been appreciated.
sequenced in our laboratory and determined to be Pgp is a versatile xenobiotic pump that was first
identical to its liver counterpart (unpublished ob- discovered in cancer cells (reviewed in [11]). Pgp
servations). In addition, the pattern of metabolites functions to make certain cancer cells resistant to
produced from several CYP3A4 substrates, and the several chemotherapeutic agents by pumping them
Fig. 1. Localization of CYP3A in human small bowel mucosa. Full thickness specimens of proximal jejunum were obtained from a human
organ donor, formalin fixed, and reacted with a polyclonal antibody that recognizes CYP3A4. The biopsy is oriented with lumen above and
the serosa below. CYP3A4 (dark staining) is detected only in mature epithelial cells (enterocytes) lining the villi and is not present in the
crypt cells, or in other cell types present in the mucosa. Within enterocytes, the highest concentration of CYP3A4 appears to be near the
absorptive surface, just below the brush border.
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out of the cells, maintaining intracellular concen- can therefore not be assumed at present that charac-
trations at sublethal levels (MDR stands for multiple teristics of Pgp transport determined in cells other
drug resistance). Pgp is expressed in a variety of than enterocytes will be directly applicable to oral
normal (non-cancerous) human tissues, including drug absorption.
liver, brain, adrenal gland, kidney and intestinal tract
epithelia [12]. In the small bowel, Pgp is present on
the apical membrane of the mature epithelial cells 2. Transport function of intestinal Pgp
and is not detectable in the crypt cells (Fig. 2). Pgp
is oriented in the apical membrane to pump xeno- 2.1. Effect on drug absorption
biotics from inside the cells back into the lumen of
the intestine (i.e., a ‘‘countertransport’’ function) The demonstration of Pgp in enterocytes provides
[13]. In humans (as opposed to rodents), there is only a mechanism to account for prior observations
one MDR1 gene, and it is generally assumed that concerning intestinal (non-biliary) excretion for cer-
intestinal Pgp is functionally identical to Pgp present tain xenobiotics. For example, erythromycin [24],
in other epithelial cells and in cancer cells. Pgp digoxin [24] and some b-blockers [25] and anti-
appears to have approximately the same molecular biotics [26–29] undergo active secretion from blood
weight in human intestinal cells as in other cell types into the small bowel intestinal lumen, and appear to
(as judged by mobility on polyacrylamide gels) [14– be substrates for Pgp [5,21,30]. Direct evidence that
16]. However, the complete coding region of human Pgp inhibits the absorption of orally administered
intestinal Pgp cDNA has not been sequenced to the drugs comes from several sources. First, several
author’s knowledge. Kinetic data regarding chemical investigators have used isolated loops of rat jejunum
inhibition of enterocyte Pgp vs. Pgp in other cell to study the absorption of compounds in the absence
types is sparse and somewhat conflicting [16–23]. It and presence of inhibitors of Pgp. One study [31]
Fig. 2. Localization of P-glycoprotein in a human small bowel villus tip. The above tissue was frozen without formalin fixation (accounting
for the poorer histology compared with Fig. 1) and reacted with an antibody that recognizes P-glycoprotein. Pgp (the black staining) is
detected only in the apical brush border membrane of the enterocytes. Pgp is therefore in close proximity to CYP3A4 (Fig. 1) at the apex of
the enterocyte. Reproduced with permission from the authors of reference [12].
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showed that the absorption of etoposide was sig- 2.2. Studies with Caco-2 cells
nificantly enhanced in the presence of an antibody
directed to Pgp (applied to the luminal surface). The human colon cancer cell line, Caco-2, has also
Other studies have tested the ability of chemical been used to study the potential role of Pgp in
inhibitors of Pgp to influence the absorption of influencing the oral absorption of drugs. Caco-2 cells
xenobiotics in isolated loops of rat jejunum. In their form confluent and polarized monolayers when
recent review, Tsuji and Tamai [32] presented a maintained in culture and differentiate towards the
figure (reproduced in Fig. 3) that summarized data mature small bowel enterocyte phenotype. A variety
indicating that certain drugs have slower rates of of devices are commercially available to facilitate the
absorption across rat intestinal mucosa than would be establishment of polarized monolayers of Caco-2
predicted by their lipophilicity alone. Many of these cells with separate apical (corresponding to the
drugs are now known to be substrates for Pgp, and lumen of the intestinal tract) and basal (corre-
most were shown to have more rapid absorption sponding to the serosal side) compartments. Drugs
when administered with the Pgp inhibitor cyclos- are then added to one side of the monolayer (usually
porin A (Fig. 3). It is interesting that the presence of the apical side to mimic absorption) and the rates of
cyclosporin A did not result in a shift back to the transport or diffusion to or from either media com-
absorption rate predicted by lipophilicity alone in partment is measured. Functional Pgp is expressed
most cases (Fig. 3). It is possible that the inves- along the apical surface of Caco-2 cell monolayers
tigators did not use sufficiently high concentrations and has been shown to mediate efflux from the
of cyclosporin A to achieve complete inhibition of basolateral to apical media compartments of some
Pgp function (the concentrations used were not drugs in this model [17,18,20–22,25,33]. Recent data
given). Alternatively, it may be that Pgp is one of support the idea that countertransport proteins other
multiple countertransport proteins responsible for the than Pgp are also present in Caco-2 cells, and may
relatively poor absorption of these compounds. be involved in the transport of xenobiotics that are
Fig. 3. Relationship between lipid solubility and the rate of absorption from the lumen of rat small bowel for a variety of different
compounds. The results shown with the squares represent the relationship between intestinal absorption clearance (ka) observed from the in
situ jejunal loop in the presence (solid) and absence (hollow) of cyclosporin A and octanol-buffer (pH 7.0) partition coefficients (log D) that
were determined [32]. 1, atenolol; 2, nadolol; 3, acetamide; 4, celiprolol; 5, acebutolol; 6, doxorubicin; 7, timolol; 8, sulfathiazole; 9,
quinidine; 10, sulfamethoxazole; 11, digoxin; 12, cyclosporin A; 13, vinblastine; 14, b-estradiol and 15, verapamil. Reproduced with
permission from the authors [32].
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also transported by Pgp [21,34]. A countertransport patient variation in oral clearance of cyclosporin A.
protein termed MRP (multidrug resistance-associated Patients with higher enterocyte concentrations of Pgp
protein) has recently been reported to be present in tended to have lower oral clearances (Cl /F) of
Caco-2 cells [35]. cyclosporin A. Variation in enterocyte concentrations
of Pgp accounted for 17% of the variation in oral
2.3. In vitro–in vivo correlations clearance in this patient population, and the contribu-
tion of Pgp was highly significant ( p , 0.001).
The most direct data supporting a role for intesti- Interestingly, a 10-fold inter-patient variation in
nal Pgp in limiting the oral availability of drugs in enterocyte content of CYP3A4 had no detectable
man has been provided recently from our research effect on the oral clearance of cyclosporin A in these
group [36]. We have developed techniques that allow studies.
quantitation of the enterocyte content of Pgp in
patients and in normal healthy volunteers [7]. A
fiberoptic endoscope is passed through the subject’s 3. Mechanism of intestinal Pgp action
mouth into the first portion of the small bowel (the
duodenum) and several small ( , 5 mg wet weight) 3.1. Effect on cyclosporine bioavailability
‘‘pinch’’ biopsies of duodenal mucosa are obtained.
The subject’s throat is sprayed with an anesthetic and The simplest explanation for the observed in vivo
the subject receives light sedation prior to the findings with cyclosporin A is that Pgp functions to
procedure, which lasts for about 15 min. The mucos- prevent the complete absorption of the drug and that
al biopsies obtained are then homogenized and the the vast majority of metabolism of cyclosporin
whole homogenate is subjected to immunoblot analy- occurs in the liver. Although this may be the case,
sis. The blots are simultaneously developed with several studies have suggested that the intestine can
antibodies to Pgp, CYP3A4 and villin [7,14]. Villin be a very substantial site for metabolism of orally
is a constitutive enterocyte-specific protein whose administered cyclosporin A [6,39–41]. An alternate
level of expression appears to be relatively constant possibility is that Pgp may not prevent complete
across individuals [7]. Enterocyte levels of Pgp and absorption of cyclosporin A, but may control the
CYP 3A4 can therefore be estimated by normalizing extent of intestinal metabolism of the drug. Although
the signals on the immunoblots for biopsy content of this is largely speculation, there are some data that
villin. This is necessary because the number of intact support this theory.
enterocytes can vary substantially among biopsies First, CYP3A4 and Pgp appear to be functionally
from the same individual [7]. For example, a deep integrated, as there is great overlap between sub-
biopsy will have much fewer enterocytes than a strates for CYP3A4 and Pgp [42–44]. For example,
shallow biopsy. Without correction for biopsy villin cyclosporin A is a well characterized substrate for
content, biopsies obtained from the same patient can both CYP3A4 [45] and P-glycoprotein [46]. Indeed,
have a several-fold variation in the content of to the author’s knowledge, there has not yet been a
CYP3A4 or Pgp. single compound identified that is transported by Pgp
Using this technique, we have shown that the that has been shown not to be a substrate for
enterocyte concentrations of CYP3A4 and Pgp vary CYP3A4. Likewise, the author is unaware of a
by up to 10-fold among kidney transplant recipients substrate of CYP3A4 that has been conclusively
[14], and vary somewhat less among normal healthy shown not to be transported by Pgp. It should be
adults not taking medication [37]. This technique has noted, however, that one recent study has suggested
also allowed us to begin to define the roles of Pgp that the CYP3A4 substrate, midazolam, may not be
(and CYP3A4) in determining the oral availability of transported by Pgp [34], and relatively few drugs
drugs. In a recent study of 20 stable renal transplant have been tested in this regard.
recipients [14], we found that variation in intestinal Second, CYP3A4 and Pgp are co-localized in the
expression of Pgp and variation in liver expression of small bowel (being present in villus enterocytes and
CYP3A4 (measured with the erythromycin breath not in crypt cells (Fig. 1A–B). Moreover, data
test [38]) accounted for 73% of the observed inter- obtained in rat and man suggest that CYP3A en-
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zymes are localized primarily at the apex of the
enterocytes, just below the brush border containing
Pgp [10,47]. Although CYP3A4 is presumably
bound within the endoplasmic reticulum (ER), much
of the ER containing the enzyme appears to be
closely associated with the apical plasma membrane.
Finally, Pgp and CYP3A4 appear to be coordi-
nately regulated in some instances [48]. It has been
pointed out that CYP3A4 and Pgp genes are located
close to one another on the same chromosome, and
Fig. 4. Potential functional relationships between enterocyte P-that tumors expressing Pgp tend to also express glycoprotein and CYP3A4. In order to gain entry into the body
CYP3A4 [43]. In addition, at least some xenobiotics (and into portal blood), most CYP3A4 and Pgp substrates must
have been shown to be inducers of both CYP3A4 traverse small bowel epithelial cells (enterocytes) located near the
tips of the intestinal villi. It appears that most drugs that areand Pgp in human enterocytes in vivo [37] or in a
substrates for CYP3A4 are also transported by Pgp. In addition,human intestinal cell line [48]. However, there does
metabolites generated by CYP3A4 may have higher affinity for
not appear to be a correlation between the relative Pgp than for the parent compounds (see discussion in text). The
levels of expression of CYP3A4 and Pgp in a given relative level of activity of Pgp may potentially influence the
individual. That is, a person can have relatively high extent of oral availability of CYP3A4 substrates by (a) preventing
parent drug diffusion across the apical brush border membraneenterocyte CYP3A4 expression while having rela-
(i.e., preventing absorption), (b) prolonging the duration oftively low enterocyte Pgp expression (and vice versa)
absorption (and hence increasing the extent of exposure of drug to[14]. One confounding issue is that there does not
enterocyte CYP3A4), or (c) by selectively removing metabolites
appear to be a correlation between enterocyte levels from within the enterocyte (that are themselves substrates for
of CYP3A4 mRNA and CYP3A4 protein [7], in- CYP3A4), preventing product inhibition of primary drug metabo-
lism.dicating that regulation of the enzyme is not at the
level of transcription. This conclusion is also sup-
ported by the recent observation that grapefruit juice
causes a marked fall in the enterocyte concentration metabolites of cyclosporin A generated in the en-
of CYP3A4 protein while it does not influence the terocyte in vivo are substrates for Pgp (a reasonable
enterocyte concentration of CYP3A4 mRNA [49]. but untested hypothesis), the affinity of the transpor-
Although purely speculative, other dietary factors ter for the metabolites would have to be significantly
may also influence CYP3A4 protein levels within the greater than for parent cyclosporin A. Similar ob-
enterocyte. Mechanisms underlying the regulation of servations were made by Gan et al. [51] in Caco-2
Pgp expression in enterocytes have not been ex- cell monolayers. They noted that the major primary
amined to date. metabolite of cyclosporin A produced within the
Fig. 4 illustrates several mechanisms whereby the cells was selectively transported across the apical
functions of CYP3A4 and Pgp might be synergistic cell membrane into the apical medium. This occurred
in limiting the oral availability of substrates. An in the presence of micromolar concentrations of
intuitively attractive idea is that metabolites of cyclosporin A, again supporting the concept that
compounds generated by CYP3A4 are better sub- metabolites of cyclosporin A generated by CYP3A4
strates for Pgp than are the parent compounds. There are superior substrates for Pgp compared to the
is some data with cyclosporin to support this hypoth- parent compound. Indeed, it is a very attractive idea
esis. We have performed studies in isolated loops of to speculate that CYP3A4 is present in small bowel
rat jejunum in vivo which demonstrated that primary enterocytes to create better substrates for Pgp. Sub-
metabolites generated by CYP3A4 were selectively strates that escape countertransport by Pgp and gain
pumped from the enterocyte back into the gut lumen entry into the enterocyte would encounter CYP3A4
[50]. Transport of cyclosporin A metabolites just beneath the brush border at the apex of the
occurred in the presence of relatively high (pre- enterocyte [10,47]. Conversion of parent drug to
sumably millimolar) concentrations of cyclosporin A more highly transportable (and hence less readily
in the intestinal lumen. Assuming that the primary absorbed) metabolites at the cell apex would logical-
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ly result in pumping of the metabolites into the however, that a similar human study with nifedipine
intestinal lumen and elimination in stool. (a well characterized CYP3A4 substrate) failed to
show enhanced availability after distal small bowel
3.2. Interaction of Pgp with other CYP3A4 administration [55]. A confounding factor is that the
substrates /metabolites absorptive surface area per centimeter of bowel is
considerably lower in the distal small bowel com-
There are several potential mechanisms whereby pared to the proximal small bowel, and the levels of
Pgp could influence the extent of metabolism of Pgp may be increased [56]. These factors may
CYP3A4 substrates during absorption. Based on a function to reduce absorption of some CYP3A4
variety of data outlined above, Pgp appears to substrates in distal small bowel, off-setting the effect
influence the rate of absorption of several substrates. of reduced CYP3A4 levels.
By prolonging absorption, the duration of exposure The third way in which Pgp could influence first-
of the drug to the enzyme within the enterocyte is pass metabolism might be by pumping primary
prolonged. If the enzyme is saturated during absorp- metabolites out of the enterocyte, preventing sec-
tion, prolonging absorption should increase the ex- ondary metabolism of substrates by CYP3A4. This
tent of metabolism at the level of the intestine. For could have the effect of accelerating the rate of
example, if the duration of absorption of cyclosporin primary metabolism if the affinity of the metabolites
A is largely determined by the level of P-glycopro- for Pgp transport was greater than that for the parent
tein, patients with relatively high enterocyte Pgp drug. For example, data outlined above suggests that
levels could have increased intestinal metabolism of primary metabolites of cyclosporin A are selectively
cyclosporin A simply as a result of a prolonged transported out of enterocytes into the gut lumen and
absorption phase. Therefore, the effect of high that the affinity for transport is greater for the
enterocyte Pgp levels would be reduced oral availa- metabolites than for parent cyclosporin A. Secondary
bility of parent cyclosporin A, even though absorp- metabolism of cyclosporin A is extensive, and
tion could ultimately be complete. Gan et al. [51] CYP3A4 appears to be the principal enzyme in-
noted that the rate of metabolism of cyclosporin A volved in secondary metabolism [57]. Hence, pa-
was greater when the drug was added to the apical tients with high Pgp expression might have relatively
(compared to the basolateral) side of Caco-2 cells, high rates of primary metabolism (and lower oral
and proposed that this was due to an effect of Pgp in availability of parent cyclosporin A) but relatively
determining the ‘‘residence time’’ of the drug in the low rates of secondary metabolism as a consequence
cells. of the rapid transport of metabolite out of the
The second way in which the level of P-glycopro- enterocyte. In this case, the level of Pgp would affect
tein in the enterocyte could control the extent of the extent of product inhibition and influence the oral
metabolism of a substrate would be if, by reducing availability of a drug, without necessarily changing
the rate of absorption, the result was to shift absorp- the duration of the absorption phase, or the ana-
tion from the proximal small bowel to more distal tomical site of absorption.
segments. The total mass of CYP3A4 per gram of
mucosa falls significantly in distal areas of the small
bowel [52]. Hence, moving absorption to more distal 4. Future directions
areas may result in less first-pass metabolism. This
principle is supported by a study performed in The potential interactions and synergy between
rabbits using the CYP3A4 substrate, diltiazem [53]. CYP3A4 and P-glycoprotein remain largely specula-
Oral availability was significantly greater when tive, mainly because methods available to study such
diltiazem was infused into the distal small bowel interactions are limited at present. Mouse knock-out
than when it was administered to the proximal small models are likely to provide some insight, but it
bowel. This appeared to be the direct result of a should be remembered that rodents have two ex-
reduction in metabolism during absorption. Similar pressed Mdr1 genes and may not be a good model
results have been obtained in man with the CYP3A4 for the human situation. Relatively selective chemi-
substrate, nefazodone [54]. It should be noted, cal inhibitors of Pgp or CYP3A4 that do not inhibit
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